Characteristics of deaths associated with kratom use - PubMed (original) (raw)
. 2019 Sep;33(9):1102-1123.
doi: 10.1177/0269881119862530. Epub 2019 Aug 20.
Affiliations
- PMID: 31429622
- DOI: 10.1177/0269881119862530
Characteristics of deaths associated with kratom use
John M Corkery et al. J Psychopharmacol. 2019 Sep.
Abstract
Background: Kratom (Mitragyna speciosa Korth) use has increased in Western countries, with a rising number of associated deaths. There is growing debate about the involvement of kratom in these events.
Aims: This study details the characteristics of such fatalities and provides a 'state-of-the-art' review.
Methods: UK cases were identified from mortality registers by searching with the terms 'kratom', 'mitragynine', etc. Databases and online media were searched using these terms and 'death', 'fatal*', 'overdose', 'poisoning', etc. to identify additional cases; details were obtained from relevant officials. Case characteristics were extracted into an Excel spreadsheet, and analysed employing descriptive statistics and thematic analysis.
Results: Typical case characteristics (n = 156): male (80%), mean age 32.3 years, White (100%), drug abuse history (95%); reasons for use included self-medication, recreation, relaxation, bodybuilding, and avoiding positive drug tests. Mitragynine alone was identified/implicated in 23% of cases. Poly substance use was common (87%), typically controlled/recreational drugs, therapeutic drugs, and alcohol. Death cause(s) included toxic effects of kratom ± other substances; underlying health issues.
Conclusions: These findings add substantially to the knowledge base on kratom-associated deaths; these need systematic, accurate recording. Kratom's safety profile remains only partially understood; toxic and fatal levels require quantification.
Keywords: Mitragynine; cause of death; characteristics; kratom; toxicology.
Similar articles
- Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia.
Singh D, Müller CP, Murugaiyah V, Hamid SBS, Vicknasingam BK, Avery B, Chear NJY, Mansor SM. Singh D, et al. J Ethnopharmacol. 2018 Mar 25;214:197-206. doi: 10.1016/j.jep.2017.12.017. Epub 2017 Dec 15. J Ethnopharmacol. 2018. PMID: 29248450 - Mitragynine concentrations in two fatalities.
Domingo O, Roider G, Stöver A, Graw M, Musshoff F, Sachs H, Bicker W. Domingo O, et al. Forensic Sci Int. 2017 Feb;271:e1-e7. doi: 10.1016/j.forsciint.2016.12.020. Epub 2016 Dec 23. Forensic Sci Int. 2017. PMID: 28089300 - Characterization of urinary protein profile in regular kratom (Mitragyna speciosa korth.) users in Malaysia.
Jasim RK, Hassan Z, Singh D, Boyer E, Gam LH. Jasim RK, et al. J Addict Dis. 2022 Apr-Jun;40(2):235-246. doi: 10.1080/10550887.2021.1981122. Epub 2021 Nov 8. J Addict Dis. 2022. PMID: 34747343 - From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction.
Hassan Z, Muzaimi M, Navaratnam V, Yusoff NH, Suhaimi FW, Vadivelu R, Vicknasingam BK, Amato D, von Hörsten S, Ismail NI, Jayabalan N, Hazim AI, Mansor SM, Müller CP. Hassan Z, et al. Neurosci Biobehav Rev. 2013 Feb;37(2):138-51. doi: 10.1016/j.neubiorev.2012.11.012. Epub 2012 Dec 1. Neurosci Biobehav Rev. 2013. PMID: 23206666 Review. - Kratom use and mental health: A systematic review.
Swogger MT, Walsh Z. Swogger MT, et al. Drug Alcohol Depend. 2018 Feb 1;183:134-140. doi: 10.1016/j.drugalcdep.2017.10.012. Epub 2017 Dec 7. Drug Alcohol Depend. 2018. PMID: 29248691 Review.
Cited by
- An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations.
McCurdy CR, Sharma A, Smith KE, Veltri CA, Weiss ST, White CM, Grundmann O. McCurdy CR, et al. Expert Rev Clin Pharmacol. 2024 Jan-Jun;17(2):131-142. doi: 10.1080/17512433.2024.2305798. Epub 2024 Jan 29. Expert Rev Clin Pharmacol. 2024. PMID: 38217374 Free PMC article. Review. - Health Effects Associated With Kratom (Mitragyna speciosa) and Polysubstance Use: A Narrative Review.
Striley CW, Hoeflich CC, Viegas AT, Berkowitz LA, Matthews EG, Akin LP, Iheanyi-Okeahialam C, Mansoor U, McCurdy CR. Striley CW, et al. Subst Abuse. 2022 May 20;16:11782218221095873. doi: 10.1177/11782218221095873. eCollection 2022. Subst Abuse. 2022. PMID: 35645563 Free PMC article. Review. - Translating Kratom-Drug Interactions: From Bedside to Bench and Back.
Tanna RS, Cech NB, Oberlies NH, Rettie AE, Thummel KE, Paine MF. Tanna RS, et al. Drug Metab Dispos. 2023 Aug;51(8):923-935. doi: 10.1124/dmd.122.001005. Epub 2023 Jun 7. Drug Metab Dispos. 2023. PMID: 37286363 Free PMC article. Review. - Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats.
Hassan R, Sreenivasan S, Müller CP, Hassan Z. Hassan R, et al. Front Pharmacol. 2021 Jul 12;12:708019. doi: 10.3389/fphar.2021.708019. eCollection 2021. Front Pharmacol. 2021. PMID: 34322028 Free PMC article. - The Chemistry of Kratom [Mitragyna speciosa]: Updated Characterization Data and Methods to Elucidate Indole and Oxindole Alkaloids.
Flores-Bocanegra L, Raja HA, Graf TN, Augustinović M, Wallace ED, Hematian S, Kellogg JJ, Todd DA, Cech NB, Oberlies NH. Flores-Bocanegra L, et al. J Nat Prod. 2020 Jul 24;83(7):2165-2177. doi: 10.1021/acs.jnatprod.0c00257. Epub 2020 Jun 29. J Nat Prod. 2020. PMID: 32597657 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical